In 2010, 3M Skin and Nasal Antiseptic was launched to help address the rising concern about surgical site infections caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. During the last three years, a growing body of evidence has proven the positive outcomes of utilizing this intervention as part of preoperative nasal preparation to reduce the risk of surgical site infection.

“At the time of launch, clinical studies had shown the antiseptic killed 99.5 percent of S. aureus in the nares in one hour and maintained that level for at least 12 hours, an important benefit for patients undergoing surgery who may be at risk for infection,” said DeAnn Hammer, Marketing Manager, 3M Infection Prevention Division. “We’ve now seen another handful of studies that continue to point to 3M Skin and Nasal Antiseptic as an important part of preoperative skin preparation to reduce the risk of SSI.”

Five distinct, third-party studies have confirmed 3M Skin and Nasal Antiseptic’s efficacy – both individually, and as part of a preoperative bundle of interventions focused on infection reduction.

Staphylococcus aureus is the leading cause of surgical site infections with approximately 80 percent of S. aureus infections caused by the patient’s own nasal flora. As the only product designed to work within the preoperative process to quickly and effectively reduce S. aureus colonization in the nares, healthcare providers can be confident their patients are entering surgery with a reduced risk of infection.